OPKO Health (OPK) CEO Buys $36,361.20 in Stock

OPKO Health (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 7,720 shares of the firm’s stock in a transaction on Friday, June 29th. The shares were purchased at an average cost of $4.71 per share, with a total value of $36,361.20. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at $14,454,759.21. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, June 27th, Phillip Md Et Al Frost purchased 10,000 shares of OPKO Health stock. The stock was bought at an average cost of $4.75 per share, with a total value of $47,500.00.
  • On Thursday, June 21st, Phillip Md Et Al Frost purchased 30,000 shares of OPKO Health stock. The stock was bought at an average cost of $4.54 per share, with a total value of $136,200.00.
  • On Monday, June 18th, Phillip Md Et Al Frost purchased 14,299 shares of OPKO Health stock. The stock was bought at an average cost of $4.34 per share, with a total value of $62,057.66.
  • On Friday, June 15th, Phillip Md Et Al Frost purchased 10,000 shares of OPKO Health stock. The stock was bought at an average cost of $4.42 per share, with a total value of $44,200.00.
  • On Monday, June 11th, Phillip Md Et Al Frost purchased 10,000 shares of OPKO Health stock. The stock was bought at an average cost of $4.22 per share, with a total value of $42,200.00.
  • On Wednesday, June 6th, Phillip Md Et Al Frost purchased 30,000 shares of OPKO Health stock. The stock was bought at an average cost of $4.05 per share, with a total value of $121,500.00.
  • On Thursday, May 31st, Phillip Md Et Al Frost purchased 3,900 shares of OPKO Health stock. The stock was bought at an average cost of $3.76 per share, with a total value of $14,664.00.
  • On Friday, May 25th, Phillip Md Et Al Frost purchased 10,000 shares of OPKO Health stock. The stock was bought at an average cost of $3.70 per share, with a total value of $37,000.00.
  • On Wednesday, May 23rd, Phillip Md Et Al Frost purchased 40,000 shares of OPKO Health stock. The stock was bought at an average cost of $3.73 per share, with a total value of $149,200.00.
  • On Monday, May 21st, Phillip Md Et Al Frost purchased 90,000 shares of OPKO Health stock. The stock was bought at an average cost of $3.82 per share, with a total value of $343,800.00.

Shares of OPKO Health opened at $4.76 on Wednesday, MarketBeat reports. OPKO Health has a 1-year low of $2.66 and a 1-year high of $7.24. The company has a current ratio of 1.10, a quick ratio of 0.94 and a debt-to-equity ratio of 0.03. The firm has a market cap of $2.63 billion, a P/E ratio of -16.41 and a beta of 1.70.

OPKO Health (NASDAQ:OPK) last announced its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.05. OPKO Health had a negative return on equity of 8.76% and a negative net margin of 31.27%. The firm had revenue of $254.90 million for the quarter, compared to the consensus estimate of $236.90 million. During the same period in the previous year, the business earned ($0.06) EPS. The firm’s revenue for the quarter was down 4.3% on a year-over-year basis. equities research analysts forecast that OPKO Health will post -0.27 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the stock. Teachers Advisors LLC grew its stake in OPKO Health by 3.5% during the 4th quarter. Teachers Advisors LLC now owns 489,837 shares of the biotechnology company’s stock worth $2,400,000 after buying an additional 16,675 shares during the last quarter. Boulegeris Investments Inc. grew its stake in OPKO Health by 7.4% during the 1st quarter. Boulegeris Investments Inc. now owns 245,605 shares of the biotechnology company’s stock worth $779,000 after buying an additional 16,825 shares during the last quarter. Xact Kapitalforvaltning AB grew its stake in OPKO Health by 58.2% during the 1st quarter. Xact Kapitalforvaltning AB now owns 57,921 shares of the biotechnology company’s stock worth $184,000 after buying an additional 21,300 shares during the last quarter. Swiss National Bank grew its stake in OPKO Health by 3.9% during the 1st quarter. Swiss National Bank now owns 584,200 shares of the biotechnology company’s stock worth $1,852,000 after buying an additional 22,100 shares during the last quarter. Finally, California Public Employees Retirement System grew its stake in OPKO Health by 2.8% during the 4th quarter. California Public Employees Retirement System now owns 811,356 shares of the biotechnology company’s stock worth $3,976,000 after buying an additional 22,200 shares during the last quarter. Hedge funds and other institutional investors own 23.81% of the company’s stock.

OPK has been the subject of several recent research reports. BidaskClub raised OPKO Health from a “strong sell” rating to a “sell” rating in a research report on Thursday, April 19th. Barrington Research reissued a “buy” rating and issued a $7.00 price target on shares of OPKO Health in a research report on Wednesday, May 9th. Cantor Fitzgerald reissued a “buy” rating and issued a $20.00 price target on shares of OPKO Health in a research report on Tuesday, May 8th. Zacks Investment Research lowered OPKO Health from a “buy” rating to a “hold” rating in a research report on Friday, May 25th. Finally, ValuEngine raised OPKO Health from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $10.21.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Insider Buying and Selling by Quarter for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply